Is TTK Healthcare overvalued or undervalued?

As of 2 July 2025, TTK Healthcare's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a price-to-earnings (PE) ratio of 27.55, a price-to-book value of 1.83, and an EV to EBITDA ratio of 34.04. These ratios suggest that while the company is not undervalued, it also does not present an attractive buying opportunity at this time.
In comparison to its peers, TTK Healthcare's PE ratio is lower than that of Sun Pharma, which is considered expensive at 35.25, but higher than Cipla, which is rated attractive with a PE of 22.92. Additionally, TTK's PEG ratio of 2.20 aligns closely with its peer average, indicating that growth expectations are factored into its current valuation. Notably, TTK Healthcare has underperformed the Sensex on a year-to-date basis, with a return of -2.69% compared to the Sensex's 6.75%, which further reinforces the notion of its fair valuation status.